Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)
Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Main objective:
To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26
weeks, starting on the first day of chemotherapy (CT), delays tumoral spread and increases
progression-free survival.
Secondary objectives:
To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26
weeks, starting with the onset of chemotherapy, increases global survival, improving the
response rates to treatment with CT + RT (radiotherapy) and reduces the incidence of venous
thromboembolism (VTE).
Phase:
Phase 2
Details
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra